Drugs / hydroxyethylstaerke
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01538173 | Jan 2007 → Oct 2011 | — | Max Dieterich | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hydroxyethylstaerke | “Our approach to decrease SSI after BR was the application of an i.v. isotonic crystalloid solution, 6% hydroxyethylstaerke (HES) as a diminished peripheral blood flow and...” NCT01538173 ↗ |
| Known as | HES | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01538173 ↗ |
| Route | Intravenous | “application of an i.v. isotonic crystalloid solution” NCT01538173 ↗ |